Ichor to present double feature at Undoing Aging Conference in Berlin

Posted on Posted in Uncategorized

LaFayette, NY – The 2018 Undoing Aging Conference, co-hosted by SENS Research Foundation and Michael Greve’s Forever Healthy Foundation, is a scientific forum focused on the cellular and molecular repair of age-related damage. It provides a platform for leading researchers from around the world to share their work in stem cells, senescent cells, immunotherapies, biomarkers, and drug discovery.

Ichor Therapeutics will present two invited talks featuring portfolio companies Antoxerene and Lysoclear, which focus on small molecule drug discovery for senescence, and enzyme therapy research for age-related macular degeneration, respectively.

Antoxerene successfully deployed patent-pending protein expression technology to identify first-in-class small molecule hits on the senescence associated p53/FOXO4 pathway early this year. These early findings will be presented by Ichor Chief Science Officer Adam Blanden. Over the past two years, Lysoclear has completed pivotal proof-of-concept studies demonstrating efficient removal of lipofuscin from retinal pigmented epithelial cells of the eye using enzyme therapy. Eye lipofuscin accumulates with age and is a molecular hallmark of age-related macular degeneration. This work will be presented by Ichor Chief Executive Officer Kelsey Moody.

The Undoing Aging Conference is a much anticipated extension of the highly successful SENS Foundation conference series. We feel privileged to be giving two invited talks and look forward to engaging other researchers in the field of aging about the remarkable progress that had been made in the past few years.

– Kelsey Moody, CEO

Ichor Therapeutics has established itself as a premier contract research organization, providing drug discovery and development services with a specialization in aging pathways and mechanisms. Additional members of the Ichor research team will be attending Undoing Aging 2018 to provide information about Ichor’s expansive pre-clinical infrastructure and offer a sneak peak at Ichor’s soon to be released protein expression tool suite, RecombiPure.